1.Comparison of HbA1c in Chinese patients with type 1 or type 2 diabetes randomized to twice daily insulin lispro low mix 25 or twice daily human insulin mix 30/70.
Yan LI ; Qiang LI ; Cheng-jiang LI ; Chang-jiang WANG ; Yi-man ZHENG ; Maher ISSA ; Jia ZHANG
Chinese Medical Journal 2009;122(21):2540-2546
BACKGROUNDGlycemic control prevents onset and progression of diabetes-related long-term complications. The objective of this study was to demonstrate that twice daily insulin lispro low mix 25 is noninferior to twice daily human insulin mix 30/70 in achieving glycemic control as measured by hemoglobin A1c (HbA1c), from baseline to endpoint, in patients with type 1 or 2 diabetes.
METHODSIn this phase IV, crossover, open-label, multicenter study, 117 Chinese patients with diabetes were randomly assigned to one of two treatment sequence groups. One group received 12-week treatment with twice daily human insulin mix 30/70 followed by 12-week treatment with twice daily insulin lispro low mix 25, while the other group received the reverse treatment sequence. HbA1c, baseline-to-endpoint change in HbA1c, proportion of patients achieving target HbA1c RESULTSA statistically significant reduction (P CONCLUSIONThe results support noninferiority of twice daily insulin lispro low mix 25 versus twice daily human insulin mix 30/70 in HbA1c control in Chinese patients with type 1 or 2 diabetes.
Adolescent
;
Adult
;
Aged
;
Asian Continental Ancestry Group
;
Diabetes Mellitus, Type 1
;
drug therapy
;
metabolism
;
Diabetes Mellitus, Type 2
;
drug therapy
;
metabolism
;
Drug Administration Schedule
;
Female
;
Glycated Hemoglobin A
;
metabolism
;
Humans
;
Hypoglycemic Agents
;
administration & dosage
;
Insulin
;
administration & dosage
;
analogs & derivatives
;
Insulin Lispro
;
Male
;
Middle Aged
;
Young Adult